


Paxlovid Summary

- Paxlovid is a highly effective treatment against COVID-19. In clinical trials, Paxlovid was shown to have an 88% reduction in hospitalization and death.
- Paxlovid must be started within 5 days of symptom onset.
- Paxlovid may be given to individuals who are pregnant.
- Obtain a full medication list to evaluate for drug interactions.
- Renal dose adjustments are needed. It is not recommended for severe renal or hepatic impairment.

Paxlovid Usage In New Mexico



About 35% of all patients who have a reported positive COVID-19 test are treated with Paxlovid.

Our most effective tool for preventing outcomes such as hospitalization and death in COVID-19 positive patients is Paxlovid.

NMDOH continues to receive calls from patients who report difficulty finding a COVID-19 provider who can evaluate and treat their illness.

Eligibility

Paxlovid (Nirmatrelvir/ritonavir) is recommended for adults and pediatric patients 12 years and older weighing at least 40 kg (88 lb) with positive SARS-CoV-2 test results who are at high risk for progression to severe COVID-19. Paxlovid is not recommended for patients with severe renal or hepatic impairment.

The FDA has released a *Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers* to assist in the evaluation of patients.

<https://www.fda.gov/media/158165/download>

Who Qualifies as High Risk?

Examples of high-risk patient characteristics include older adults (age 50 yr+), asthma, smoking (current or former), overweight, diabetes, pregnant, immune compromised, mental health disorders, substance use disorders, and cardiovascular disease.

For a full list of conditions and patient characteristics that increase a patient's risk for severe COVID-19 disease, please visit: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/>

Dosing

Paxlovid is taken twice daily for 5 days. Paxlovid does not require renal dose adjustment. The manufacturer has both a standard dose pack and a renal dose pack available.

OFFICE OF THE SECRETARY



eGFR (CKD=EPI formula)	Dosage of (Nirmatrelvir/Ritonavir)
>60 ml/min	300/100 by mouth twice daily for 5 days
30-60 ml/min	150/100 by mouth twice daily for 5 days
<30 ml/min	Not recommended

Drug Interactions

Paxlovid contains ritonavir. To evaluate for drug interactions, clinicians should obtain a complete medication list. The NIH guidelines advise that “drug-drug interactions that can be safely managed should not preclude the use of this medication”. <https://www.covid19-druginteractions.org/>

Paxlovid COVID-19 Rebound

COVID-19 rebound may occur in patients treated with Paxlovid 2-8 days after the initial recovery and is characterized by a recurrence of symptoms or a new positive viral test after having tested negative. In the Paxlovid clinical trial, a small number of Paxlovid and placebo patients had COVID-19 rebound. **There was no increased occurrence of hospitalization or death. There was no evidence of SARS-CoV-2 resistance to Paxlovid. Retreatment with a second course of Paxlovid is NOT recommended.**

Patients who experience COVID-19 rebound should be instructed to:

- Isolate again at least 5 days
 - May end isolation if fever resolved for 24 hours and symptoms are improving
- Wear a mask for 10 days after rebound symptoms started
- Contact a healthcare provider if COVID-19 rebound symptoms

persist or worsen

https://emergency.cdc.gov/han/2022/pdf/CDC_HAN_467.pdf

Pharmacist Prescribing of Paxlovid


On July 6th, the FDA updated the Paxlovid EUA to allow for pharmacist prescribing of Paxlovid. Pharmacist prescribing does have certain limitations to ensure appropriate patient assessment. Pharmacists must:

1. Obtain recent health records assessing kidney and liver function.
2. Obtain a complete medication list.
3. Refer patients to a physician, advanced practice nurse, or physician assistant if there is insufficient information to assess renal/hepatic function, drug interactions, or for patients who require modifications due to drug interactions.

Pharmacists may contact your clinic to obtain health records or to refer patients who require modifications to existing medications. Please note that some pharmacies may not be able to offer treatment evaluation of patients with COVID-19 due to staffing.

OFFICE OF THE SECRETARY

COVID-19 Treatment Provider and Pharmacy Finder



New Mexico Department of Health has a tool that assists patients in locating COVID-19 treatment providers and pharmacies. <https://findatreatmentnm.com/>

To have your clinic listed as a COVID-19 treatment provider, please contact covid.therapeutics@state.nm.us